Peter Savas

Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study

Jennifer Mooi, Fiona Chionh, Peter Savas, Jessica Da Gama Duarte, Geoffrey Chong, Stephen Brown, Rachel Wong, Timothy J Price, Alysson Wann, Effie Skrinos, John M Mariadason, Niall C Tebbutt

Journal article  |  2021  |  CLINICAL CANCER RESEARCH

PURPOSE: To assess the efficacy and safety of dual antiangiogenesis agents, bevacizumab plus trebananib, without chemotherapy, in ..

Molecular mechanism of ipatasertib (IPAT) and its combination with atezolizumab (atezo) in patients (pts) with locally advanced/metastatic triple-negative breast cancer (aTNBC)

Peter Schmid, Delphine Loirat, Peter Savas, Enrique Espinosa, Valentina Boni, Antoine Italiano, Shane White, Victor Laliman, Geraldine Strasser, Kui Lin, Karen Cheng, Aruna Mani, Matthew Wongchenko, Marie-Paule Sablin, Kalpit Shah

Conference Proceedings  |  2021  |  CANCER RESEARCH

A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours

Sunit Sarkar, Ben Tran, Lisa Horvath, Michael Lam, Peter Savas, Peter Grimison, James R Whittle, James C Kuo, Nicole Signal, David Edmonds, Philip Hogg, Danny Rischin, Jayesh Desai, Anne Hamilton

Journal article  |  2021  |  CANCER CHEMOTHERAPY AND PHARMACOLOGY

PURPOSE: This phase I study was conducted to evaluate the safety and Maximum Tolerated Dose of PENAO (4-(N-(S-penicillaminylacetyl..

Tumor-Infiltrating Lymphocyctes in Triple-Negative Breast Cancer Update for 2020

Lauren C Brown, Roberto Salgado, Stephen J Luen, Peter Savas, Sherene Loi

Journal article  |  2021  |  CANCER JOURNAL

ABSTRACT: Triple-negative breast cancer (TNBC) continues to represent an unmet need because of its significantly poorer outcomes, ..

Pervasive chromosomal instability and karyotype order in tumour evolution

Thomas BK Watkins, Emilia L Lim, Marina Petkovic, Sergi Elizalde, Nicolai J Birkbak, Gareth A Wilson, David A Moore, Eva Gronroos, Andrew Rowan, Sally M Dewhurst, Jonas Demeulemeester, Stefan C Dentro, Stuart Horswell, Lewis Au, Kerstin Haase, Mickael Escudero, Rachel Rosenthal, Maise Al Bakir, Hang Xu, Kevin Litchfield, et al.

Journal article  |  2020  |  NATURE

Chromosomal instability in cancer consists of dynamic changes to the number and structure of chromosomes1,2. The resulting diversi..

Clinical implications of prospective genomic profiling of metastatic breast cancer patients

Courtney T van Geelen, Peter Savas, Zhi Ling Teo, Stephen J Luen, Chen-Fang Weng, Yi-An Ko, Keilly S Kuykhoven, Franco Caramia, Roberto Salgado, Prudence A Francis, Sarah-Jane Dawson, Stephen B Fox, Andrew Fellowes, Sherene Loi

Journal article  |  2020  |  BREAST CANCER RESEARCH

BACKGROUND: Metastatic breast cancer remains incurable. Next-generation sequencing (NGS) offers the ability to identify actionable..

Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (Atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (aTNBC)

P Schmid, S Kuemmel, D Loirat, P Savas, E Espinosa, V Boni, A Italiano, S White, S Singel, N Withana, A Mani, S Li, A Harris, M Wongchenko, M Sablin

Conference Proceedings  |  2020  |  GEBURTSHILFE UND FRAUENHEILKUNDE

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Zuzana Kos, Elvire Roblin, Rim S Kim, Stefan Michiels, Brandon D Gallas, Weijie Chen, Koen K van de Vijver, Shom Goel, Sylvia Adams, Sandra Demaria, Giuseppe Viale, Torsten O Nielsen, Sunil S Badve, W Fraser Symmans, Christos Sotiriou, David L Rimm, Stephen Hewitt, Carsten Denkert, Sibylle Loibl, Stephen J Luen, et al.

Journal article  |  2020  |  NPJ BREAST CANCER

Stromal tumor-infiltrating lymphocytes (sTILs) are important prognostic and predictive biomarkers in triple-negative (TNBC) and HE..

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

Mohamed Amgad, Elisabeth Specht Stovgaard, Eva Balslev, Jeppe Thagaard, Weijie Chen, Sarah Dudgeon, Ashish Sharma, Jennifer K Kerner, Carsten Denkert, Yinyin Yuan, Khalid AbdulJabbar, Stephan Wienert, Peter Savas, Leonie Voorwerk, Andrew H Beck, Anant Madabhushi, Johan Hartman, Manu M Sebastian, Hugo M Horlings, Jan Hudecek, et al.

Journal article  |  2020  |  NPJ BREAST CANCER

Assessment of tumor-infiltrating lymphocytes (TILs) is increasingly recognized as an integral part of the prognostic workflow in t..

Validation and characterisation of prognostically significant PD-L1( ) immune cells in HPV plus oropharyngeal squamous cell carcinoma

Richard J Young, Mathias Bressel, Sandro Porceddu, Janez Cernelc, Peter Savas, Howard Liu, Damien Urban, Alesha A Thai, Caroline Cooper, Tsien Fua, Paul Neeson, Danny Rischin, Benjamin Solomon

Journal article  |  2020  |  ORAL ONCOLOGY

We previously showed in human papillomavirus positive oropharyngeal squamous cell carcinoma (HPV+OPSCC) that the presence of intra..